Clinical trials: Schizo-affective Disorder
Schizophrenia, Schizophreniform Disorder
Integrated Metacognitive Therapy in First Episode Psychosis
Insight, or lack of illness awareness, is a prominent and pressing clinical concern in the treatment and recovery of patients with psychotic disorders.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- IMT (NCT02131116)
- Testing
- Integrated Metacognitive Therapy, Treatment as Usual
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Severe Mental Illness, Schizophrenia
The Potential Efficacy of the Chinese Health Improvement Profile- A Pilot Clustered Randomised Controlled Trial
The investigators programme of research will evaluate an existing physical health care screening intervention with the aim of helping Community Psychiatric Nurses (CPN) to improve the physical health wellbeing of people with a…
- Conditions
- Severe Mental Illness, Schizophrenia, Schizoaffective Disorder, Bipolar Affective Disorder
- Trial name
- CHIP (NCT02453217)
- Testing
- Chinese CHIP, Treatment as usual
- Volunteers
- 144 people
- Sponsor
- Wai-Tong Chien
Schizophrenia, Schizoaffective Disorder
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
The purpose of this study is to determine if zonisamide SR will prevent weight gain in schizophrenic subjects who take olanzapine (Zyprexa)
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00734435
- Testing
- zonisamide SR plus olanzapine
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Orexigen Therapeutics, Inc
Schizophrenia, Schizoaffective Disorder
Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
The objective of the study is to determine whether Panax Ginseng with multiple interactions with key components of brain signaling pathway, can augment the effects of antipsychotics in Schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Tardive Dyskinesia, Insulin Resistance
- Trial name
- NCT00401089
- Testing
- Panax Ginseng
- Where
- 4 sites in Canada, United Kingdom
- Volunteers
- 60 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Schizophrenia, Schizo Affective Disorder
Transcranial Weak Current Stimulation Treatments for Working Memory Dysfunction in Schizophrenia
For the present study, Investigators will examine the efficacy of active prefrontal anodal tDCS versus placebo (sham) interventions to treat WM dysfunction in schizophrenia.
- Trial name
- NCT04637724
- Testing
- transcranial direct current stimulation (tDCS)
- Where
- Israel
- Volunteers
- 33 people
- Sponsor
- Oded Meiron
Psychosis, Schizophrenia
Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia
A study of children and adolescents (current N=100) with very early onset by age 12 (COS) of DSM-III-R defined schizophrenia with (97-M-0126) is examining the clinical, neurobiological, early neurodevelopmental, genetic, and…
- Conditions
- Psychosis, Schizophrenia, Genetic Structure, Childhood Onset Psychotic Disorders
- Trial name
- NCT00001198
- Where
- United States
- Volunteers
- 1,556 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizoaffective Disorder
Improving Care and Reducing Cost Study
The goal of the Improving Care and Reducing Cost (ICRC) Program, is to improve disease management and the overall process of care in treating the chronic illness schizophrenia in order to reduce ER visits and hospital days while…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychosis NOS
- Trial name
- ICRC (NCT02364544)
- Testing
- Relapse Prevention Plan, Daily Support Website, Computer CBT for voices and paranoia
- Where
- 8 sites in United States
- Volunteers
- 461 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia
In this trial, researchers aim to investigate if prolonged-release melatonin can facilitate the withdrawal of chronic benzodiazepine administration in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Affective Disorder
- Trial name
- SMART (NCT01431092)
- Testing
- Melatonin
- Where
- Denmark
- Volunteers
- 86 people
- Sponsor
- Lone Baandrup
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia and Related Disorders, Early Treatment-Resistance
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Schizophrenia (SZ) affects approximately 4.5 million people across the European Union (EU) and is associated with annual healthcare and societal costs of 29 billion Euros.
- Trial name
- INTENSIFY SZ (NCT05958875)
- Testing
- Clozapine, Second-line Antipsychotics (treatment as usual)
- Where
- 13 sites in Austria, Germany and 3 more
- Volunteers
- 418 people
- Sponsor
- Dr. Inge Winter
Schizophrenia, Schizoaffective Disorder
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
The purpose of this study is to evaluate epidemiological characteristics of patients that experience relapse and need an admission in psychiatric acute units across Spain.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00399334
- Testing
- antipsychotic medications
- Volunteers
- 1,607 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Schizoaffective Disorder
Switching Antipsychotics: Abrupt Discontinuation Versus Overlap
Clozapine has been demonstrated to be clinically superior to other antipsychotics in treatment-resistant schizophrenia (TRS), and is positioned as such in treatment guidelines.
- Trial name
- NCT02640300
- Testing
- Clozapine
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia
This study will compare the safety and effectiveness of three different antipsychotic medications, as well as the use of other medications to limit treatment side effects, in adults with schizophrenia.
- Trial name
- COATS (NCT00802100)
- Testing
- Olanzapine, Perphenazine, Aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia, Schizophreniform Disorder
rTMS in First Episode Psychosis
This study proposes to examine the application of rTMS for the treatment of cognitive dysfunction in FEP. This is an important population for study because if effective, rTMS may represent a preventative treatment for the…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- EmeraldThunder (NCT02131129)
- Testing
- rTMS
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Schizophrenia, Schizoaffective Disorder
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.
- Trial name
- NCT06319170
- Testing
- Olanzapine Extended Release, Olanzapine Immediate Release
- Where
- 5 sites in United States
- Volunteers
- 106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia, Schizophreniform Disorder
Optimization of Treatment and Management of Schizophrenia in Europe
The purpose of the study is optimising current treatments in schizophrenia and explore novel therapeutic options for schizophrenia.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- OPTIMISE (NCT01248195)
- Testing
- Amisulpride open label, 6-week amisulpride double blind treatment, 6-week olanzapine double blind treatment
- Where
- 26 sites in Australia, Austria and 14 more
- Volunteers
- 479 people
- Sponsor
- Rene Kahn
Schizophrenia, Schizoaffective Disorder
Cognitive Remediation in Early Phase Psychosis
The purpose of the study is to investigate the effect of a 30 hour cognitive remediation program for young patients with early phase schizophrenia spectrum disorders on cognitive, clinical and functional outcome measures.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychosis NOS
- Trial name
- NCT01546467
- Testing
- Cognitive remediation
- Where
- Norway
- Volunteers
- 50 people
- Sponsor
- Oslo University Hospital
Schizophrenia, Schizoaffective Disorder
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia
This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing…
- Trial name
- NCT00237809
- Testing
- D-serine, Cognitive Retraining (CRT)
- Where
- 2 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
- Trial name
- NCT00588731
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Yale University
Schizophrenia, Schizo Affective Disorder
Telmisartan Pilot Study on Treatment Resistant Schizophrenia
This study is a 4-week pilot study for subjects with Schizophrenia or Schizoaffective Disorder who have not experienced a significant relief of symptoms from current anti-psychotic medication.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
- Trial name
- NCT03868839
- Testing
- Telmisartan Pill
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Xiaoduo Fan